1 / 3

Betrixaban

Boc Sciences offers 330942-05-7 Betrixaban in bulk, please inquire us to get a quote for 330942-05-7 Betrixaban.<br>https://www.bocsci.com/betrixaban-cas-330942-05-7-item-90322.html<br>

bocsci2018
Download Presentation

Betrixaban

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Betrixaban - CAS 330942-05-7 Catalog number: B0084- 090322 A direct factor Xa inhibitor used as an oral anticoagulant drug. It has been prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets Factor Xa SARS-CoV-2 Molecular Formula C23H22ClN5O3 Molecular Weight 451.91 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 090322 25 mg $199In stock 0 Bulk Inquiry Add to cart Chemical Information Category Inhibitor Molecular Formula

  2. C23H22ClN5O3 Molecular Weight 451.91 Specification Properties QC Data Reference Reading     Synonyms PRT054021; PRT 054021; PRT-054021; MK-4448; MK 4448; MK4448; PRT-021; PRT 021; PRT02 1; MLN-1021; MLN 1021; MLN1021; Bevyxxa; N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarba mimidoyl)benzoyl]amino]-5-methoxybenzamide Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT00375609Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) ThromboembolismPhase 2 May 2006 Portola Pharmaceuticals Completed NCT00742859Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin Atrial Fibrillation Phase 2 October 2008 Portola Pharmaceuticals Completed NCT00999336A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment Renal ImpairmentPhase 1 July 2009 Portola Pharmaceuticals Completed NCT01229254Evaluate the Atrial Fibrillation Phase 2 September 2010 Portola Pharmaceuticals Completed Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

  3. NCT01583218Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Venous Thromboembolism (VTE) Phase 3 March 2012 Portola Pharmaceuticals Completed Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 2.2128 mL 11.0641 mL 22.1283 mL 5 mM 0.4426 mL 2.2128 mL 4.4257 mL 10 mM 0.2213 mL 1.1064 mL 2.2128 mL 50 mM 0.0443 mL 0.2213 mL 0.4426 mL https://www.bocsci.com/betrixaban-cas-330942-05-7-item-90322.html

More Related